Mr. Williams brings to Valink more than 35 years of experience in the global biopharmaceutical business, having closed more than $5 billion worth of corporate transactions, including numerous partnerships, M&A, and public and private financings. He recently served as chief executive officer of Caraway Therapeutics, a venture-backed company developing therapeutics to modulate lysosomal function for neurodegenerative and rare diseases, through the company’s acquisition by Merck & Co. at the end of 2023. Previously, he was president and chief executive officer of Tokai Pharmaceuticals, a clinical-stage oncology company; chief business officer at Dicerna Pharmaceuticals, a leading RNAi company with programs in oncology; and chief business officer and senior vice president for commercial and business development at Synta Pharmaceuticals, a clinical-stage public company focused on oncology and inflammation. Earlier in his career, Mr. Williams held various leadership positions and directed the development, commercialization and launch of several flagship brands for GSK, Hoffmann-La Roche and Lederle/Wyeth (now Pfizer), including GSK’s blockbuster Zantac® and Zofran®; Hoffmann La-Roche’s Xenical®; and Lederle/Wyeth’s global anti-infective portfolio, including Zosyn®/Tazocin®. Martin holds an MBA from Harvard Business School and an MS from the University of Manchester, UK.

Alex is a Cofounder and CEO of Diagonal Therapeutics and an Entrepreneur-in-Residence in Atlas Venture. During his 20+ year career in biotechnology, he served as COO of Dragonfly Therapeutics, CDO of Morphic Therapeutic, VP of Therapeutics at Merrimack Pharmaceuticals, and Associate Director of Drug Discovery at Biogen. Alex is an author of over 100 patents and manuscripts. He is an Associated Editor of the mAbs and serves on the Board of Directors of the Antibody Society. He has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in Biophysics from Harvard University, an M.Sc. in Molecular Biophysics, and a B.Sc. in Mathematics and Physics from the Moscow Institute of Physics and Technology.

 Alex holds a PhD degree in computational chemistry and MBA from Mannheim Business School. Alex brings more than 10 years of experience in the biotech space, being a co-founder of drug development startup himself and then moving to the VC side. He successfully invested in Biotech and Medtech startups from a VC fund RBV Capital and from CVC arm of tier 1 reinsurance company SCOR.

Irsyad is Co-Founder and CTO of Valink Therapeutics. He completed his DPhil at the University of Oxford as a protein engineer and subsequently worked on several cancer projects in the pharmaceutical consulting sector, which shape the direction of Valink's LiliumX platform. His DPhil work explored modular protein assembly technologies as a precursor to the LiliumX platform.

Arne Scheu is Co-Founder and CEO of Valink Therapeutics. Following his research on protein conjugation technologies at the University of Oxford, he founded Valink Therapeutics as a spin-out of the Department of Biochemistry with the support of the Y Combinator startup accelerator; the company combines his passions for protein engineering and drug discovery. Arne holds a DPhil (PhD) in Biochemistry from the University of Oxford, has been awarded the Rhodes Scholarship for Germany, and has been listed as Forbes 30 Under 30 Europe 2024.

‍

Rob is a cofounder of London-based Hoxton Ventures and is currently cofounding  H Tree Capital, a specialized seed tech:bio fund. He has over thirteen years in the VC industry and was previously a product manager at Google in Silicon Valley. He holds a degree in Computer Science from the University of Maryland. His notable investments include Babylon Health, Preply, Spacelift.io and several dozen others.

Hoxton Ventures is an early stage venture capital firm based in London and investing in European technology startups that can scale into large, global winners. It focuses on startups that either disrupt existing industries or invent entirely new market categories. It was the first institutional investor in Babylon Health, Darktrace and Deliveroo, and its portfolio companies have grown to an aggregate value of over $32 billion. Hoxton typically invests between $500,000 and $5 million into pre-seed and seed stage companies, and follows its capital through the life of the company. For more information please visit https://www.hoxtonventures.com.

Lars has a diverse background, with experience in both basic and translational research, as well as from the business side through the financial markets. A molecular biologist in training, Lars spent seven years at the Norwegian Radiumhospital at the Institute for Cancer Research. There, he completed his master’s degree and worked on molecular mechanisms associated with tumour development and suppression in cervical- and colorectal cancer models. Subsequently, he worked in investment banking at Arctic Securities as an Equity Research Analyst covering the healthcare sector, before joining p53 Invest as an Investment Director.

Georgia is passionate about working closely with startup founders to realize their vision through focused development, operations and fundraising resource and strategies. A seasoned M&A professional, Georgia has a deep network of corporate and institutional investors to leverage in order to help early stage companies scale.

Georgia is the founding partner of Magnet Ventures, seed investor and board member of INNFOS (exited), investor of Cloudminds (exited), seed investor of AI-Biotech companies: Valink Therapeutics (formerly LiliumX), Flux Biosciences, Regard (formerly HealthTensor), Atom Bioworks.

Mihiriban Tuna, PhD is chief executive officer of Immutrin and entrepreneur-in-residence at Cambridge Innovation Capital, a leading UK-based venture company focused on deep tech and life sciences. She previously served as chief scientific officer at Adaptate Biotherapeutics (acquired by Takeda) and SVP, Drug Discovery at F-star Therapeutics, and was an early employee at Domantis Ltd. (acquired by GSK).

‍

Alexey A. Lugovskoy, PhD is the President and Chief Executive Officer of Diagonal Therapeutics, Entrepreneur-in-Residence at Atlas Ventures, and Associate Editor of mAbs. Alex formerly served as a Chief Operating Officer at Dragonfly, Chief Development Officer at Morphic, Vice President of Therapeutics at Merrimack Pharmaceuticals, and and Associate Director of Drug Discovery at Biogen. He joined Valink’s Board of Directors in 2023, and this additional appointment highlights a close collaboration between the Scientific Advisory Board, Board of Directors, and the leadership team.

Sonia Quaratino, MD, PhD, is Executive Vice President and Chief Medical Officer at Innate Pharma, a clinical-stage biotech utilizing monoclonal antibodies, multi-specific NK cell engagers and ADCs to develop immunotherapies for cancer. Her career spans over 25 years in basic research, clinical development and translational medicine across academia, biotech and global pharmaceuticals. She has held numerous leadership positions, including serving as CMO at Kymab (until its acquisition by Sanofi) and Georgiammune Inc, and was Professor of Immunology at the University of Southampton.

Antoine Awad is Principal Executive Officer (CEO) of the public biopharma company Synlogic and a seasoned C-Level biotech executive steering drug development and organizational growth for innovative biotech, with extensive experience in CMC technical operations and CMC regulatory. Mr. Awad has deep experience in bispecific drug development and manufacturing. Prior to joining Synlogic, he held leadership positions at various biotechs, including a ten-year period at Merrimack Pharmaceuticals, where he led CMC development, manufacturing and approval of ONIVYDE® for treatment of advanced pancreatic cancer and transitioned to Ipsen Bioscience to integrate and lead global commercial manufacturing of ONIVYDE®. Tonyhas broad experience in partnerships, collaboration and M&A, most notably with Sanofi, Baxalta/Shire plc, Actavis Pharma/Teva Pharmaceutical Industries and Ipsen Bioscience.

Marc Damelin, PhD is the Chief Scientific Officer at Alphina Therapeutics and an expert in oncology drug discovery and development. Previously Marc served as VP and Head of Biology at Mersana Therapeutics, a clinical-stage biotech developing ADCs to treat cancer. Prior to that he worked for a decade in ADC discovery and development in Pfizer's Oncology Research Unit.

Robert Lutz, PhD chief scientific officer at leading ADC company Iksuda Therapeutics, is a recognized expert in ADC discovery and development. As VP of Translational R&D at ImmunoGen, he directed the development of all ADC programs, including Kadcyla®, the first ADC to be approved for solid tumor indications.

Charles Conn is a seasoned business builder and investor. Before co-founding Monograph Capital, a life sciences venture firm, he was CEO of Oxford Sciences Innovation, a £600m deep science venture firm formed in partnership with Oxford. Charles is a technology entrepreneur and former public company CEO (Ticketmaster/Citysearch/Match.com).

He serves as Chair of Patagonia, and was previously CEO of the Rhodes Trust; before that he was senior advisor to the Gordon & Betty Moore Foundation. He began his career at McKinsey & Company, where he was a Partner. He is a graduate of Harvard Business School, Boston University, and Oxford University, where he was a Rhodes Scholar.

Innovative strategy, partnerships and market shaping executive with 15+ years of leadership experience in U.S., European, and global healthcare environments (NCDs, neuro, onco). Proven record of designing and executing strategies that simultaneously shape commercial and reputational ambition; driving high-impact campaigns that catalyze healthcare system changes; and fomenting large-scale partnerships that connect the dots between influential stakeholders and improved patient outcomes. Yale Ph.D, Fulbright Scholar, former NIH/WHO, and trade group veteran with deep networks across UN, EU and US political, academic, and health tech spheres.

Known for creative, high-impact campaigns that underpin P&R decisions; and driving innovative partnerships that address health disparities, particularly between pharma and tech.

Matt de Silva is the Chief Operating Officer of Pathos, a Series-C stage company re-engineering drug development and leveraging the power of advanced AI technologies. He is a Venture Partner at builder VC, and was the Founder of Notable Labs (2014) as well as its CEO until his transition to executive Chairman in 2020. Matt has been an advisor to Valink's founders since early in its formation.

Keith Mostov is a Professor of Cell Biology, Biochemistry and Biophysics at the University of California, San Francisco (UCSF). He also founded or co-founded several biotech companies, including Novellus DX. Prof. Mostov was a Rhodes Scholar, received his MD from Weil-Cornell Medical College and PhD with Nobel Laureate Guenter Blobel at The Rockefeller University.

Subsequently, he was a Whitehead Fellow and Principal Investigator at the Whitehead Institute, before moving to UCSF. He has worked on polymeric immunoglobulins, as well as epithelial polarity and morphogenesis.